课题基金基金详情
CircEphB4抗肝癌新机制及白藜芦醇对其的调控研究
结题报告
批准号:
81773953
项目类别:
面上项目
资助金额:
60.0 万元
负责人:
肖建勇
依托单位:
学科分类:
H3210.中药抗肿瘤药理
结题年份:
2021
批准年份:
2017
项目状态:
已结题
项目参与者:
谭宇蕙、李红、金贺、王坤、张文银、王小兰、占玉娟
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
CircRNA是一种共价成环且结构稳定的新型非编码RNA,其表达丰富且参与肿瘤等多种疾病调控,是癌症治疗潜在新靶点,然而在肝细胞癌中作用和机制不清。近来我们发现肝癌中circEphB4表达显著下调,过表达circEphB4抑制肝癌增殖和转移,转录组测序提示circEphB4下调趋化因子CCL20及其下游ERK磷酸化水平。由此我们提出:circEphB4通过调控CCL20/ERK信号通路抑制肝癌增殖和转移的新机制。进一步,我们筛选到中药单体白藜芦醇抑制肝癌细胞活力并上调circEphB4表达。因此,本项目拟进一步通过高通量测序、RNA-pull down、RNA IP、体内外实验以及临床标本分析,阐明白藜芦醇诱导circEphB4上调及其靶向调控CCL20的分子机制,揭示circEphB4调控肝癌增殖和转移的上下游机制,为确立circEphB4作为肝癌治疗新靶点和针对性药物开发提供充分科学.
英文摘要
Circular RNA (circRNA) is covalently closed non-coding RNA. As circRNA is stable, abundant, and involved in regulation of a variety of diseases such as cancer, circRNA has been become prospective novel target of cancer therapy. However, the role of circRNA in hepatocellular carcinoma (HCC) cells and the mechanism by which it functions are still unclear. Recently, we found that circEphB4 was downregulated in HCC tissues comparing with non-tumor tissues. Overexpression of circEphB4 inhibited the proliferation and metastasis of HCC cells. Transcriptome sequencing indicated that chemokine CCL20 and its downstream phosphorylated ERK is correspondingly downregulated in circEphB4-overexpressing stable HCC cell lines. Therefore, we hypothesized that circEphB4 may suppress the proliferation and metastasis of HCC cells via CCL20/ERK pathway. Further, we screened out resveratrol, a monomer of Chinese traditional herbs that inhibited the viability of HCC cells and upregulated the expression level of circEphB4. In this study, we will further elucidate how resveratrol induced the upregulation of circEphB4 and the mechanism by which circEphB4 targeted CCL20 for its regulation with high throughput sequencing, RNA-pull down and RNA immunoprecipitation, in vitro and in vivo experiments, and clinical tissue samples. By revealing the upstream and downstream signal pathways through which circEphB4 inhibits the proliferation and metastasis, this investigation will provide scientific evidence for that circEphB4 is identified as a novel target of HCC treatment and drug development.
本研究主要阐明了circEphB4抑制肝癌细胞增殖和转移的分子机制,并通过动物实验验证了circEphB4抗肿瘤潜力。另外,预实验提示白藜芦醇能够上调肝癌细胞circEphB4,而进一步实验却发现白藜芦醇上调circEphB4并不显著,将circEphB4干扰后,白藜芦醇的抗肿瘤效果也没有符合预期得到逆转。然而,有趣的是白藜芦醇能够上调肝癌细胞缝隙连接蛋白,提示增强肝癌细胞之间细胞通讯。基于此,我们将白藜芦醇联合自杀基因HSK-TK/GCV,发现白藜芦醇显著增强自杀基因对肝癌细胞旁杀伤效应,进一步动物实验也验证了两者的协同杀伤作用。问题是缝隙连接蛋白属于长半衰期蛋白,其降解主要溶酶体自噬途径,那么白藜芦醇能够上调缝隙连接蛋白,提示白藜芦醇或干预自噬,文献报道的确印证上述观点,并且理论上抑制自噬有望增效化疗杀伤肿瘤。受到启发,我们筛选了系列中药小分子,其中常春藤皂苷元,土贝母皂苷能够抑制细胞自噬,正如之前推测,协同化疗的确能够较好杀伤肿瘤细胞。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria.
Tubeimoside I 诱导的肺癌细胞死亡以及溶酶体和线粒体之间潜在的串扰。
DOI:10.1038/s41419-020-02915-x
发表时间:2020
期刊:Cell Death & Disease
影响因子:9
作者:Wang K;Zhan Y;Chen B;Lu Y;Yin T;Zhou S;Zhang W;Liu X;Du B;Wei X;Xiao J
通讯作者:Xiao J
Synergistic effect of resveratrol and HSV-TK/GCV therapy on murine hepatoma cells.
白藜芦醇与HSV-TK/GCV治疗对小鼠肝癌细胞的协同作用
DOI:10.1080/15384047.2018.1523094
发表时间:2019
期刊:Cancer biology & therapy
影响因子:3.6
作者:Xiao J;Wang X;Wu Y;Zhao Q;Liu X;Zhang G;Zhao Z;Ning Y;Wang K;Tan Y;Du B
通讯作者:Du B
Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1α
circ-EPHB4 通过抑制 HIF-1α 在肝细胞癌中的抗肿瘤作用
DOI:--
发表时间:2019
期刊:Mol Carcinog
影响因子:--
作者:Tan Y;Du B;Zhan Y;Wang K;Wang X;Chen B;We X;Xiao J
通讯作者:Xiao J
Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells
常春藤素通过损害肺癌细胞的自噬增强顺铂和紫杉醇介导的细胞毒性
DOI:10.1038/s41419-020-02880-5
发表时间:2020-08-13
期刊:CELL DEATH & DISEASE
影响因子:9
作者:Wang, Kun;Liu, Xiaodong;Xiao, Jianyong
通讯作者:Xiao, Jianyong
一石二鸟: 防己诺林碱通过提升树突状 细胞与肿瘤细胞抗原提呈能力增强抗肿 瘤免疫
  • 批准号:
    --
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    肖建勇
  • 依托单位:
白藜芦醇通过miR-330靶向调控MRP1诱导鼻咽癌放射增敏的研究
  • 批准号:
    81274145
  • 项目类别:
    面上项目
  • 资助金额:
    68.0万元
  • 批准年份:
    2012
  • 负责人:
    肖建勇
  • 依托单位:
国内基金
海外基金